Dystroglycanopathy is a major class of congenital muscular dystrophy caused by a deficiency of functional glycans on α-dystroglycan (αDG) with laminin-binding activity. Recent advances have led to identification of several causative gene products of dystroglycanopathy and characterization of their in vitro enzymatic activities.
Introduction
Dystroglycanopathy is a group of congenital muscular dystrophies that arise from glycosylation defects of α-dystroglycan (αDG). The hallmark and cause of these diseases, which include Fukuyama-type congenital muscular dystrophy, muscle-eye-brain diseases, Walker-Warburg syndrome, and congenital muscular dystrophy type 1D, are a lack of functional O-mannosyl glycans of αDG capable of binding laminin (1) (2) (3) . To date, dozens of causative gene products of dystroglycanopathy have been identified, all of which have been demonstrated or are assumed to be involved in the synthesis of the laminin-binding glycans. A plethora of O-glycans including the normal O-GalNAc mucin types and all three core types of O-mannosyl glycans, namely, M1 (Gal-β4-GlcNAc-β2-Man), M2 [Gal-β4-GlcNAc-β2-(Gal-β4-GlcNAc-β6-)Man], and M3 (GalNAc-β3-GlcNAc-β4-Man) (4) , have been identified on various sites of DG. Remarkably, the functional laminin-binding glycans were found to be exclusively carried on the core M3 at specific T317/T319 sites (5) . The formation of this innermost base structure involves at least three enzymes, namely, protein O-mannosyltransferase 1/2 heterodimer (POMT1/2), protein O-mannose β-1,4-N-acetylglucosaminyltransferase 2 (POMGNT2/AGO61), and β-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2) (6) (7) (8) . Notably, this trisaccharide core can be further phosphorylated at the 6-position of O-mannose by protein-O-mannose kinase (POMK/SGK196) (6) .
On the other hand, functional laminin binding is known to require a polymeric Xyl-GlcA repeat sequence, the elongation of which is catalyzed by LARGE (9) . Since the Xyl-GlcA repeat is released from the core upon chemical hydrolysis of phosphoester linkages by hydrogen fluoride treatment, the laminin-binding glycan synthesized by LARGE was inferred to be extended from the phosphorylated core M3 via the phosphate added by POMK. However, the exact structural element bridging this missing link is lost by such chemical treatment and thus remains undescribed until very recently (10) (11) (12) (13) .
A major technical problem in identifying the elusive structural module linking the phosphorylated core M3 and the polymeric GlcA-Xyl units is the limiting mass spectrometry (MS) sensitivity in detecting a very large glycan or glycopeptide carrying multiple negative charges in the form of HexA and phosphate. Most of the analytical work to date has used recombinant αDG truncated at the C-terminus to different extents but all containing at least the first 10 amino acid residues following the putative endogenous furin cleavage site R312 that releases the N-terminal domain (5, 14) . For convenience in the purification, the truncated C-terminus is also commonly fused to antibody Fc or other tags, which may or may not be further removed during sample preparation. Such a strategy typically yielded very large and heterogeneous tryptic glycopeptides that contain additional O-glycosylated serine/threonine downstream of the critical T317/T319 attachment sites (Fig. 1) , which hampered high-quality MS/MS sequencing and unambiguous data interpretation (10) . Alternatively, a tryptic site can be engineered by converting the first threonine after T319 to lysine (T322K), which would not only further truncate the target tryptic glycopeptide carrying T317/T319, but at the same time abolish the extra O-glycosylation. After further glycosidase treatment to remove mucin-type O-glycans, a recent study using such truncated αDG constructs expressed in and purified from mouse NIH 3T3 cells succeeded for the first time in detecting the further modified phosphorylated core by MS analysis in negative ion mode (11) .
It was shown that a tandem ribitol phosphate unit (RboP-RboP) can be attached to the terminal GalNAc of phosphorylated core M3, which can then be extended further by repeating HexA-Pent units, consistent with the proposed model that is supported by in vitro enzymatic assays of the involved causative gene products including isoprenoid synthase domain containing (ISPD), fukutin (FKTN), and fukutin-related protein (FKRP) (11) . It also indicated that ISPD is a cytidine diphosphate ribitol (CDP-Rbo) synthase and FKTN transfers a Rbo5P from CDP-Rbo to phosphorylated core M3, thereby providing an acceptor site for FKRP to form the RboPRboP tandem repeat. The possibility has also been raised that TMEM5 serves as a xylosyltransferase using the RboP-RboP structure as an acceptor site to initiate the first step of Xyl-GlcA repeat sequence synthesis (10).
However, this rather unique glycosylation structural motif has yet to be detected intact on αDG expressed in other cells, including the widely used HEK293T cells or indeed any human cell type, owing to the aforementioned technical difficulties. It is not known whether there is structural variation associated with core M3 modifications that contributes to the tissue-specific glycosylation status of αDG (4) and impacts on its functions as an extracellular matrix receptor in the brain, heart, skeletal muscle, and kidney, or correlates with its reduced expression in human breast and colon cancers in relation to tumor progression (15) .
By adopting similar truncation and tryptic site engineering of recombinant αDG, we demonstrate a highly sensitive analytical workflow from in-gel digestion to direct nano-LC-MS 
Generation of knockout cells using CRISPR/Cas9 genome editing
The construction of vector (pKO) for TMEM5-KO cells was performed basically in accordance with previous reports (17, 18) . The 1.5-kb fragment of the human TMEM5 gene used for the 5′ arm was amplified by PCR from HCT116 cell genomic DNA using the primers 5′-ggggtacCAAATTATGCAGTCATTTGC-3′ and 5′-ctagctagcGATAAGAAACGAGCAGAGCC-3′, and then subcloned between the KpnI and NheI sites to create the pKO 5′ arm (hTMEM5). The 1.5-kb fragment of the TMEM5 gene used for the 3′ arm was amplified similarly using the primers 5 ′ -ataagaatgcggccGCCCTGTACTGCCTATTCTC-3 ′ and 5 ′ -ataagaatgcggccgcGTTGACATATGCATTGCAATC-3′, and then subcloned into the NotI site of the pKO 5′ arm 
Expression of Fc-fused αDG recombinant proteins
HEK293T as well as HCT116 and its mutated cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 at 37°C. For the expression of αDG373(T322R)-Fc, cells were grown overnight and transfected using Polyethylenimine Max (Polysciences, Inc.), in accordance with a previous report (19) . Protein expression was performed in DMEM supplemented with 10% FBS treated with a Protein G affinity column (GE Healthcare) to remove immunoglobulin G. The secreted Fc-fused αDG fragments in culture medium were purified using a Protein G affinity column.
Western blot
Western blots were performed as described previously (16, 20) .
Interaction analyses by pull-down assay
Immunoprecipitation was performed in accordance with procedures described previously (17) . At with PBS, and then heated at 65°C in Laemmli's sample buffer. Immunoprecipitates were subjected to SDS-PAGE and immunoblotting.
Identification of O-glycopeptides
The gel band containing αDG was excised and subjected to in-gel digestion by sequential steps of reduction with 10 mM dithiothreitol at 37C for 1 h, alkylation with 50 mM iodoacetamide in 25 mM ammonium bicarbonate buffer for 1 h in the dark at room temperature, destaining with 50% acetonitrile in 25 mM ammonium bicarbonate buffer, and then overnight digestion with sequencing-grade trypsin (Promega) at 37C.
The digested products were sequentially extracted with distilled water, 1% formic acid, and 50% acetonitrile/1%
formic acid, dried down, and then redissolved in 0.1% formic acid for further cleaned up by ZipTip C18 ; maximum injection time = 120 ms.
RESULTS AND DISCUSSION
The identification of additional modifications on phosphorylated O-glycans of αDG expressed in
HEK293T cells
To facilitate direct detection and sequencing of the αDG glycopeptides carrying the target O-glycans, we have opted for an analytical strategy that would preserve as much of the native O-glycosylation and other modifications as possible without introducing any chemical cleavages or glycosidase digestions prior to the MS analysis. Our choice as minimum manipulation was truncation of αDG at R373 and fusion with Fc for secretion and ease of purification ( Fig. 1 and supplemental Fig. S1 ). The resulting Fc-tagged and purified proteins appeared as two major bands on SDS-PAGE at positions corresponding to approximately 35 kDa and just above 50 kDa (Fig. 1) , neither of which was stained by IIH6, an anti-DG antibody recognizing lamininbinding glycans, as would be expected from the apparent size. Following in-gel tryptic digestion and recovery of peptides/glycopeptides from the gel, we initially searched for the target glycopeptide Q313-R337, but were unsuccessful. Hence, we decided to introduce T322R mutation to shorten the resulting tryptic glycopeptide further and to confine the O-glycosylation to only T317 and T319, which have been implicated as sites carrying the functional laminin-binding glycans based on a mutagenesis study (5) . Although the T322R substitution may affect the overall O-glycosylation occupancy and heterogeneity, previous study has shown that functional laminin-binding glycans could still be formed at T317 and T319 of the T322R mutant expressed in mouse NIH 3T3 cells (17) . We then anticipated finding the resulting Q313-R322 and its companion A323-R337 tryptic glycopeptides by searching among the MS 2 spectra for the presence of respective peptide core ions.
However, we succeeded in identifying only the A323-R337 glycopeptides, all of which were O-glycosylated to various extents, including glycoforms that carried an additional phosphate, which could be assigned as phosphorylated core M3 (supplemental Fig. S2 ). No evidence could be found for the presence of any additional glycan modifications in this tryptic glycopeptide that contains T328, T329, and S336.
We suspected that the failure to detect the target Q313-R337 peptide core ion may have been due to an unknown modification of the peptide core itself, particularly at the nascent N-terminus generated by an endogenous cleavage. Our search strategy was modified accordingly and extended to use several of the expected peptide y ions, which led to the identification of a peptide core with a mass discrepancy of minus 17 u localized to the N-terminus, likely due to pyroglutamylation of the terminal glutamine residue. In fact, a total of over 8000 MS 2 spectra containing the modified peptide core ion at m/z 551.8038
2+
were filtered out using this strategy, which comprised 673 redundant spectra that could be collectively assigned to 65 unique precursor glycoforms (Table S1 ). From the compiled data, it was clear that there were glycoforms carrying only the core M1/M2 without an additional phosphate, some of which might correspond instead to mucin-type O-GalNAc cores. These non-phosphorylated core-type structures were difficult to distinguish unambiguously by current HCD/CID MS 2 analyses alone and were not pursued further. We focused our efforts instead on glycoforms that contain at least a phosphorylated core M3 structure. Among the major structures satisfying this criterion were the glycoforms carrying two phosphorylated core M3 moieties, with and without additional modifications (Table S1 , Fig. 2 ).
All of the spectra of this series contain the same sets of ions corresponding to i) HexNAc (Table S1) Fig. 2D ). This critical oxonium ion at m/z 940.2 was more prominent in the corresponding trap CID MS 2 spectrum (Fig. 3D) .
The complementary trap CID MS 2 spectra were in general characterized by prominent losses of terminal substituted and unsubstituted HexNAc, thereby producing the common doubly and singly charged peptide core ions retaining two phospho-Hex and 1-3 HexNAc (as annotated in Fig. 3A-D) . In particular, the with GroP-or fully extended HexA-Xyl-RboP-RboP- (Fig. 4) . Moreover, the glycoforms with both T317 and T319 occupied were also more prominent than those with only single-site occupancy.
Establishment of KO cells of individual gene products causative of dystroglycanopathy
ISPD-, TMEM5-, FKTN-, or FKRP-deficient cells were established by using the CRISPR/Cas9 genome editing of HCT116 cells, a colon cancer cell line known to express the laminin-binding glycans on αDG (15) . As expected, individual KO cells exhibited no laminin-binding glycans (Fig. 5A) , whereas the target product expression rescued the defect (supplemental Fig. S4 ). It has been reported that ISPD is a cytosolic protein for the synthesis of CDP-Rbo (11, 13) , while FKRP, FKTN, and TMEM5 are located at the Golgi apparatus (21) (22) (23) (24) .
These three Golgi enzymes were not functionally compensating one another (supplemental Fig. S4 ). Since FKRP exists as a homodimer and in multimeric protein complexes (21), we conducted analyses of the interactions among these causative gene products by a pull-down assay (Fig. 6) . 
The additional modifications on phosphorylated O-glycans of αDG expressed by HCT116 cells lacking individual causative gene products of dystroglycanopathy
Taking advantage of the established fragmentation pattern, particularly the diagnostic oxonium ions, we were able to rapidly filter out relevant glycopeptide spectra for manual assignment and confirmed the similar presence of RboP/GroP modifications on phosphorylated core M3 attached to T317/T319 of αDG373(T322R)-Fc expressed in HCT116 cells (Table S1 ). However, unlike HEK293T cells, fully extended HexA-Pent-RboPRboP-HexNAc could not be found among the αDG glycoforms identified for WT HCT116 cells or any of its derived mutants. This probably reflects the observation that HCT116 cells express a higher level of endogenous laminin-binding glycans relative to HEK293T cells and thus the HexA-Pent-primed core would be readily extended, albeit not fully on the truncated αDG373(T322R)-Fc constructs, rendering their detection difficult.
Moreover, in HCT116 cells, the glycoforms with single RboP, two RboP, and one RboP + one GroP modifications were mostly detected in the FKRP mutant, or at much higher abundance in the FKRP mutant relative to the WT (Fig. 7) , consistent with the lack of further extension and consequent accumulation due to impaired FKRP activity. It should also be pointed out that, in cases where two RboP could be found without
HexA-Pent, they were not found as a tandem repeat unit but rather as a single RboP on each phosphorylated core M3 (supplemental Fig. S3B ). Likewise, no supporting evidence could be found for a tandem RboP-GroP in either direction (supplemental Fig. S3C ).
The absence of any RboP unit in ISPD and FKTN mutants is expected since the former is required to synthesize the CDP-ribitol, whereas the latter is the transferase suggested to be responsible for the addition of
RboP from CDP-ribitol onto phosphorylated core M3 (11) (12) (13) . More puzzling is the near absence of this substituent also in the TMEM5 mutant. TMEM5 was shown to be able to transfer Xyl from UDP-Xyl to CDP- 
CONCLUSION
In this study, using our nano-LC-MS/MS strategy that allows for the parallel acquisition of both HCD and trap CID MS supplemental Table S1 ) are plotted here. Table S1 for details and actual data). The red bands indicate the glycoforms with compositions consistent with carrying 1-2 phosphorylated core M3, with and without additional glycosyl residues. Glycoforms of the same composition with additional RboP and GroP substituents are represented by green and blue bands, respectively. Only one glycoform with both GroP and RboP was detected and is represented here as a green band. The glycoforms
